SELOL is an original Polish discovery, it has no equivalents in treatment

The clear demand for new compounds of selenium of lower toxicity than that of sodium selenite (IV) resulted in preparing a synthesis of selenitetriglycerides from chemically modified sunflower oil. SELOL it is a mixture of selenitetriglycerides obtained by incorporating selenic acid (IV) into molecules of fatty acids from plant oil

It is the first preparation known since 1992 that contains +4 selenium of such interaction. It has strong prooxidative and anticancer properties thanks to selenium (IV) built in dioxaselenolane and tetraoxaselenolane rings

Using it in treatment may decrease the risk of lifestyle diseases such as: cancer, cardiovascular diseases, multiple sclerosis, diabetes, rheumatism and many other diseases caused by oxidative stress and redox state disorder in cells

Showing chelation properties - removes heavy metals and radioactive isotopes from the organism, and prevents their accumulation in the body,  e.g. strontium, mercury, cadmium, lead, cesium

Due to the presence of selenium (IV), the preparation neutralizes the multidrug resistance of all cancer cell lines investigated so far. The medicinal dose recommended in cancer treatment is 3,0 mg of Se(IV)/kg body mass. The toxicity o selenitetriglycerides in comparison to known non-organic selenium (IV) compounds, e.g. sodium selenite (IV), is 30 times lower. Therefore, after concluding clinical studies, it can be safely used in treatment, especially since even in high doses ranging to 20mg of Se(IV)/kg body mass, it does  not damage healthy cells in laboratory animals. Also, sodium selenite (IV) shows  an undesirable property - 3.5 mg of Se(IV)/kg body mass is a lethal dose- it is equally effective in damaging cancer and healthy cells by means of necrosis (dirty death)

Selenitetriglycerides described above, organic compounds of selenium(IV), damage cancer cells in a natural manner by means of apoptosis and pose no threat to healthy cells, even in doses 10 times higher

The first stage of their operation on cancer cells is their prooxidative, not antioxidative activity, which after 4-6 hours turns to antioxidation as a result of activating the second line of antioxidative defense by selenoenzymes. In order to damage a cancer cell, the redox state has to increase to the level of -170mV and the metabolism of a cell has to be directed to the path of apoptosis. applying selenium(II) to cancer patients causes redox state much more difficult to control

It has been proven years ago that excess in antioxidants is harmful, especially in cancer disease, and using high doses of selenium(II) compounds can shorten the life span. Mammals are unable to deal with high doses of selenium(II). They are incapable of metabolizing and excreting it quickly enough

There is a need or selenium (IV) compounds metabolized to selenodiglutathione (compound of strong anticancer activity) and selenides (H2Se), which substitute the serine –OH group for SeH. An active form of selenocysteine is formed, and it is quickly incorporated into the active sites of selenoenzymes. After the attack of free oxygen radicals resulting from Se(IV) administration, comes a period of repairing all damages done by the reactive oxygen species, but only in healthy cells. Gamma-glutamylcysteine synthetase is blocked in cancer cells (total reduction in glutathione production). cancer cells are deprived of their first, most important line of antioxidative defense. In addition, cysteine dioxygenase is blocked. cysteine is accumulated in cancer cells. All proteins are cysteinylated and the cells are destroyed. such is the activity of organic selenium +4 compounds

Professor Piotr Suchocki, Pharm.Ph.D.
inventor of the SELOL preparation
Professor at the Department of Bioanalysis and Drug Analysis at the Faculty of Pharmacy of Warsaw Medical University, and Professor at the Department of Pharmaceutical Chemistry of the National Medicines Institute

The preparation SELOL is currently thoroughly studied in several research centers in Poland: the National Medicines Institute in cooperation with the Dept. of Bioanalysis and Drugs Analysis, the Dept. of Biochemistry and Clinical Chemistry of Warsaw Medical University, Faculty of Biology of Warsaw University, Institute of Physics Polish Academy of Sciences, Collegium Medicum of Jagiellonian University, Medical Research Centre of Polish Academy of Sciences and the National Veterinary Research Institute in Puławy have been carrying out research on the mechanisms of action and the potential usage of the original Polish invention, SELOL, in medical treatment

New research centres from all over the world are joining in. Ongoing international studies financed by the European Union are being conducted on the preparation. They are carried out at universities in Brazil, China, Finland, Germany, Norway, Poland, Portugal and Spain

For several years now, our scientists have been cooperating with two universities in Brasil (Sao Paulo and Brasilia). We continue and expand the research started regarding „intelligent” magnetic nanocapsules containing maghemite nanoparticles and SELOL. Preliminary studies have shown a four times bigger increase in cytotoxicity of SELOL in form of nanoparticles with respect to many cancer cell lines. The maghemite magnetic nanoparticles with SELOL recognize cancer cells, enter them and release SELOL. Moreover, with the use of magnetic field, they can be accumulated in a chosen section of an organism, and after entering cancer cells, treated with alternating magnetic field, they can increase their temperature to 43oC (hyperthermia effect), which effectively destroys cancer cells

The studies into SELOL’s activity on prostate cancer cells engrafted in laboratory animals have shown an approx 17% decrease in tumor within 14 days of SELOL supplementation

On the basis of the results (Institute of Industrial Organic Chemistry Branch Pszczyna) of the clinical, behavioral, clinical-chemical, and post-mortem examinations obtained during a repeated dose 90-day oral toxicity study of SELOL 5% (selenitetriglycerides) containing 50 mg/ml of Se(IV) in rats, it may be concluded that the no observed adverse effect level (NOAEL) is 2 mg/kg b.w.

National Medicines Institute
Warsaw Medical University Faculty of Biology of Warsaw University
Institute of Physics Polish Academy of Sciences
Collegium Medicum of Jagiellonian University
Medical Research Centre of Polish Academy of Sciences
National Veterinary Research Institute in Pulawy
Medical University of Lublin
Universidade de Sa˜o Paulo
Fundacao Universidade de Brasilia
Asociacion Centre de Investigacion Cooperativa en Biomateriales
Huazhong University of Science and Technology
Universitaet Leipzig
Zhejiang University

Scientists examining cancer cases from the last 30 years have estimated that in 2030 over 90% of the population will develop cancer. according to the statistics published by the International Agency of Research on Cancer, by 2017, 18 035 539 Europeans are expected to develop malignant cancer

Statistics - Poland / Europe / World